📍 X Talent 計畫 2025-1梯次 徵件說明簡報 📍 


一、計畫目標

國家科學及技術委員會推動「產業創新人才海外培訓計畫」(X Talent,以下簡稱「本計畫」),由國家實驗研究院科技政策研究與資訊中心負責執行。旨在呼應政府重點產業發展政策及配合國家科技前瞻布局,選送具潛力的產學創新種子人才,赴海外研習,汲取前瞻技術知識、創新商業模式及國際布局策略。希冀受培育之種子人才將所學應用於國內產業,協助產業轉型升級、發展技術優勢與創新能力,強化我國在全球科技與產業布局中的競爭地位。


二、徵求對象

有熱忱貢獻臺灣產業創新發展之高階人才,對於海外企業之前瞻技術、商業模式、國際策略布局等有興趣,積極拓展自己的人脈、主動探索未知領域知識,並能與跨文化、跨領域之專業人才互動良好。


三、申請資格      

  1. 國籍:申請人須有中華民國國籍

  2. 年齡:民國74年1月1日(含)後出生者。

  3. 學經歷:不限,但須對欲申請之海外企業及其須具備之技術能力有相當程度的認識,具發展潛力及自我挑戰之企圖心,並於申請時詳細說明並提出相關證明。

  4. 英文能力:能與母語人士在研習環境及生活上流暢對談及表達之英文能力程度,並於申請時檢附英語系國家學士或同等級以上之學歷證明,或民國112年(含)後取得之英文能力證明文件之一:​

    • 多益 785分或以上

    • 托福紙本測驗(ITP) 543分 / 網路測驗(iBT) 72分或以上

    • 雅思 5.5分或以上

    • 全民英檢 中高級或以上

      考量英文程度評估之有效期間
      若您的英文成績證明取得時間早於112年,請儘速進行測驗,並於報名截止期限前繳交成績證明

  5. 具有主動積極、獨立思考與作業能力,能與團隊充分溝通合作,且勇於與不同文化、技術背景的專業人才進行交流,對於將所學有服務熱忱,且可實際貢獻臺灣產業者。

  6. 曾參與國科會產學研鏈結中心計畫(價創計畫)、研發成果萌芽計畫(萌芽計畫)、科研創業案源發掘及育成推動計畫(科創計畫)、創新創業激勵計畫(FITI計畫)等國科會科研創業相關計畫者尤佳。


四、申請方式

  1. 申請人須至計畫網站線上申請,報名系統網址:
    https://xtalent.stpi.narl.org.tw/xtalent/index​

  2. 請務必於報名截止日期前於報名系統送出,逾期不受理。

  3. 請依線上系統登錄格式內容,詳實完整填寫中英文資料並檢附相關證明文件。

  4. 申請人須覓兩位推薦人,並於報名系統如實填寫推薦人聯絡資訊。
    本計畫辦公室將請推薦人協助確認相關資訊。

  5. 網路報名資料一經送出不得修改,請務必確認申請內容是否已完整填寫並附上所有附件。
     


五、甄選程序與審查方式

  • 報名申請
    申請人於申請時,須選擇1個或多個欲前往之海外公司研習志願,於線上系統提交中英文構想書,並針對選擇的第1研習志願提出研習構想。
  • 三階段審查
    為使甄選流程公平公正,本計畫之各階段甄選,將由本計畫辦公室邀請相關領域專家及企業代表組成「評選委員會」進行甄選。
    1. 構想書審查
      公告構想書審查結果後,將通知通過審查者培訓與選訓活動細節與研習計畫書審查資訊。
       
    2. 培訓與選訓
      通過構想書審查的候選人方獲得參與本計畫辦理之培訓與選訓資格,候選學員應全程參與選訓,於活動期間建立創新創業人脈、學習提案規劃與產業分析,並逐步完成研習計畫書。
       
    3. 研習計畫書審查
      以欲申請之研習志願為主軸,依指定之格式完成英文研習計畫書,並於計畫辦公室規定之期限內繳交。
       
  • 海外公司面試
    通過研習計畫書審查的候選人,得與通過研習計畫書之研習志願公司進行面試,並視需要進行電話或視訊訪談。本梯次面試時程依本計畫辦公室公告為主。
  • 核定公告
    本梯次實際核定學員人數將於海外公司面試結果與審查會議決定。獲選學員與本計畫辦公室簽訂合約後,將由本計畫辦公室協助簽證申請事宜,前往海外研習單位參加研習計畫。
上述程序如有異動,請依本計畫辦公室公告為主。
 

六、補助方式

  1. 補助金額
    本計畫補助學員赴外研習期間之生活費,補助金額以新臺幣150萬元為原則,國外研習期間少於1年者,按比例發放。(請務必於行前衡量研習地區之消費水準與個人消費習慣)
  2. 前項補助生活費之核發分兩期撥付
    • 第一期:第1至第6個月之補助生活費。雙方於簽訂合約且學員完成補助生活費請領手續後,於雙方約定之補助起始日前後30個日曆天內,將第一期補助生活費匯入學員指定之本人國內帳戶。
    • 第二期:第7至第12個月之補助生活費。學員應依本計畫辦公室規定時程內繳交期中自評表,經本計畫辦公室依研習單位之期中考核文件考核通過後,始撥付第二期補助生活費至學員指定之本人國內帳戶。

七、權利義務

  1. 本計畫為國科會為補助臺灣人才赴外研習之計畫,故優先補助取得本國學歷及未曾受領政府公費補助出國之申請人,且曾受本計畫(包含LEAP計畫)補助者不得再次申請。

  2. 申請人於申請日過去一年內,不得為欲申請之研習企業之員工、董監事或負責人,並應在申請時提供聲明文件,切結無該情況,必要時應出具相關勞健保投保紀錄證明之。

  3. 公告入選之學員赴海外研習前,須參與行前培訓及團隊凝聚活動,並與本計畫辦公室簽署合約。若無法完成合約簽署或者主動放棄簽署,視同放棄參與海外研習權利。

  4. 入選學員除應履行本計畫簡章之相關事項外,亦應確實遵守雙方簽署之合約與國科會相關規定。

  5. 入選學員於簽署合約時,應覓具中華民國國民身分之連帶保證人一人,並配合辦理對保。連帶保證人須符合以下兩個條件之一,於簽約時提供相關證明文件:(1)於我國現職服務機構服務2年以上且最近之全年薪資所得在60萬元以上(2)具有公告現值250萬元以上並位於我國之不動產所有權。另,已擔任本計畫學員連帶保證人且尚未解除或履行完擔保責任者,不得參加本計畫培訓。

  6. 前項連帶保證人若有下列情形之一,不得擔任學員之連帶保證人:(1)領取政府各類公費獲獎學金赴國外進修且尚未完成返國義務者(2)具有雙或多重國籍者(3)學員之配偶。

  7. 受本計畫補助至美國研習者,限定申請J-1簽證赴美,以J-1以外簽證赴美,計畫不予補助。

  8. 由於入選學員赴海外研習作業受簽證作業時程影響,確切赴海外時間依據入選學員之入境簽證文件為準,至遲須於本計畫辦公室公告之時程內抵達選定之海外研習機構。

  9. 入選學員赴海外研習若受簽證影響,無法取得本計畫規範之簽證赴外研習,恕不補助。如有特殊情況,請先知會計畫辦公室並徵得同意,計畫辦公室保留最終解釋和決定權。

  10. 學員於本計畫赴外研習期間,不得從事與研習目的無關之活動(包含原職)。若因故無法繼續參與本計畫之研習,除經本計畫辦公室書面同意外,須依合約負返還已受領之費用及相關賠償責任。

  11. 學員於本計畫赴外研習期間內應於指定期間內依規定繳交期中自評表及期末報告,並通過審查(報告格式、內容,依本計畫辦公室公告為主)。如學員報告未通過期中考核或期末報告審查,須依合約返還生活補助費並終止研習。

  12. 本計畫係國科會補助之研習計畫,國科會保留計畫執行方式與執行與否之最終決定權,包含但不限於本計畫辦公室配合國科會因天災、傳染病或其他不可抗力之事由或基於其他政策考量下片面終止本計畫。

  13. 獲本計畫補助之學員應負擔返國義務,返國義務包含返國服務、計畫宣傳義務與配合計畫辦公室後續追蹤,學員應於研習結束後5年內完成。其中返國服務之年限必須與所受領補助期限相同,計畫宣傳義務及後續追蹤內容依計畫辦公室公告為主。如完成研習之學員無法完成前述義務,本計畫保留請求全額生活補助費用、研習費用及損害賠償求償之權利。

  14. 國科會或本計畫辦公室不為結束研習之學員安排工作,學員須自行洽談覓職事宜。

  15. 其他學員權利義務以合約規範內容為準。


八、其他注意事項

1.本計畫之相關資訊與公告請密切注意本計畫網站:
   https://xtalent.stpi.narl.org.tw/index
   聯絡窗口:財團法人國家實驗研究院  科技政策研究與資訊中心
                    產業創新人才海外培訓計畫辦公室
   聯絡電話:(02)2737-7427、(02)2737-7950
   電子信箱:xtalent@narlabs.org.tw​
   聯絡地址:106214 臺北市大安區和平東路二段106號14樓

2.本計畫簡章如有未盡事宜,本計畫辦公室及國科會隨時保留修訂公布及解釋之權利。


📍 X Talent 計畫 2025-1梯次 徵件說明簡報 📍 

X Talent 2025 1st Batch Host Companies List
查詢
Applied Materials

Applied Materials, Inc. is an American corporation that supplies equipment, services and software for the manufacture of semiconductor chips for electronics, flat panel displays for computers, smartphones, televisions, and solar products.

Algen Biotechnologies, Inc.

Algen, a venture-backed preclinical stage biotech company, is using CRISPR to uncover disease-driving RNA messages to find treatments for cancer and diseases with high unmet needs. Originated from UC Berkeley, Algen’s research group focuses on developing and applying novel functional genomics technologies to address scientific challenges in drug discovery and deliver innovative, patient-centric medicines for the toughest-to-treat diseases.

Apeximmune Therapeutics Inc.

Apeximmune Therapeutics is a pre-clinical stage biotechnology company that is harnessing the power of the immune system to treat human disease. Based in Burlingame, CA, Apeximmune discovers and pioneers novel therapeutic antibodies that modulate immune cell activity to elicit durable, lasting efficacy in cancer and autoimmune disease. Our team integrates expertise in immunology, tumor cell biology, and protein biochemistry and engineering to provide therapies that can transform patients’ lives. We currently have several therapeutic antibody assets in various stages of preclinical development, with the aim to complete our initial IND package in the coming year.

AcuraStem Inc.

AcuraStem is a preclinical-stage company focused on neurodegenerative diseases. It is advancing novel therapeutic approaches for ALS and FTD using patient-derived stem cell models. AcuraStem has developed the iNeuroRx platform, which utilizes human iPSC-derived cells to mimic neuromuscular and neurodegenerative neuron diseases such as ALS and FTD.

Coastar Therapeutics Inc.

Coastar Therapeutics introduces a groundbreaking gene delivery platform poised to revolutionize cell and gene therapy. This innovative bioengineered cell membrane platform leverages the cell membrane as a Trojan horse, cloaking biological drugs to enhance efficacy and facilitate repeated dosing. The platform, showcased in a YouTube video (link: https://youtu.be/g-wfibqLOY8), amalgamates the strengths of LNP and exosomes.

Cellentia Inc.

Cellentia is a biotech startup committing to fight against metastatic cancers.  We have a unique technology for culturing circulating tumor cells from solid tumors for doing drug screening and monitoring acquired resistance to cancer treatments.  We use this technology to help drug developers identify the best cancer drugs against metastatic cancers and also do our own in-house drug discovery.

CancerFree Biotech, Ltd.

CancerFree Biotech develops 3D tumor organoid culture systems from patient blood samples, using these organoids to test cancer therapeutics. Our proprietary technology serves as a precision medicine tool for creating personalized treatment plans and is also used in drug development research to evaluate drug efficacy. CancerFree Biotech is incorporated in Delaware and operates a subsidiary in Taiwan, with offices in both New York City and Taipei.

Chain Reaction Ltd.

Chain Reaction is engineering the future of disruptive blockchain and privacy technologies.
We accelerate compute performance, enabling companies to adopt and scale solutions to the world’s most complex problems.
Products:
EL3CTRUM is our Blockchain product line, starting with the most efficient hashing ASIC on the market, optimized for high-performance, high efficiency, and low-power, and is the heart of our hashboards and systems. EL3CTRUM delivers optimal payback time.
3PU™ is our Privacy product, dramatically accelerating real-time operations of Privacy Enhancing Technologies on encrypted data, transforming the cloud into a trusted environment, and enabling new verticals to adopt the cloud at scale, including financial institutions, healthcare & big pharma, defense & government, oil & gas, and more.
Purpose-built and custom-designed, our solutions power the next generation of secure, scalable, green computing to help protect people, privacy, and the planet.
Mission
To radically accelerate complex technological solutions for blockchain and privacy technologies.
Vision
To empower data centers and cloud providers to adopt scalable technologies that protect people, privacy, and the planet.

Delta Electronics India Pvt. Ltd.

Delta, founded in 1971, is a global provider of power and thermal management solutions. Its mission statement, "To provide innovative, clean and energy-efficient solutions for a better tomorrow," focuses on addressing key environmental issues such as global climate change. As an energy-saving solutions provider with core competencies in power electronics and automation, Delta's business categories include Power Electronics, Mobility, Automation, and Infrastructure.

Delta offers some of the most energy efficient power products in the industry, including switching power supplies with efficiency over 90%, telecom power with up to 98%, and PV inverters with up to 99.2% efficiency. We have also developed the world‘s first server power supply certified as 80 Plus Titanium.

Headquartered in Taiwan, we regularly invest over 8% of our annual sales revenues in R&D and have worldwide R&D facilities in China, Europe, Japan, Singapore, Thailand, and the U.S.

Delta is a frequent recipient of international awards and related recognition for innovation, design, and continuous dedication to ESG. Since 2011, Delta has been listed on the DJSI World Index of Dow Jones Sustainability™ Indices for 13 consecutive years. Delta has also won CDP with double A List for 3 times for its substantial contribution to climate change and water security issues and named Supplier Engagement Leader for its continuous development of a sustainable value chain for 7 consecutive years.

In response to the challenge of climate change, Delta will remain committed to the research and development of innovative, energy-saving products, solutions and services that contributing substantially to the sustainable development of mankind.

Eos BioInnovation, LLC

Eos BioInnovation incubates and invests in projects in the field of regenerative medicine (e.g., cell & gene therapy, tissue engineering & biomaterials, molecules promoting endogenous regeneration mechanisms or helping to stop or reverse the body's degeneration processes and enabling technologies along the value chain that accelerate regenerative medicine applications) primarily from the Harvard and Boston biotech ecosystem, as well as from other top academic and research institutions. 

We are financially supported by our primary institutional partner, Panacea Venture, a $600M+ investment firm focused on healthcare investments.  We have already made two investments from the Harvard network (a neuromodulation startup from Boston Children’s Hospital and a T cell reconstitution company from Mass General Hospital/Paulson School of Engineering & Applied Science) and one investment from the University of California San Francisco (an early stage senolytics startup leveraging novel immune approaches to address age-related diseases to improve human health span).  We continue to look for exciting early stage biotech projects and are particularly interested in company formation opportunities where we launch promising companies with leading scientists and motivated entrepreneurs.

Fujitsu Research of America Inc

Fujitsu is one of the world's largest IT services providers and has a significant presence in Japan (No.1) and globally (No. 9). The company is known for its supercomputers, servers, and other high-performance computing solutions. Fujitsu also offers a wide range of enterprise software, cloud services, and cybersecurity solutions.

Throughout its history, Fujitsu has been involved in various technological innovations and has contributed to global electronics and computing industries. The company continues to focus on digital transformation and emerging technologies like artificial intelligence and the Internet of Things.

Fujitsu Research of America plays a crucial role in Fujitsu's global research and development efforts, focusing on creating innovative solutions for the North American market and contributing to Fujitsu's worldwide technological advancements.

Instant NanoBiosensors

Instant NanoBiosensors (INB) is an innovative life sciences company that has developed next generation, cost-effective ultra-sensitive real-time immunoassay platforms that advance precision health for life sciences research and diagnostics. Our platform , Light Sensing Biomarker Analyzer, based on patented FOPPR (Fiber Optic Particle Plasmon Resonance) and IN-Chip (auto-flowing microfluidic chip) technologies with 35+ global patents ( US, UK, Europe, China, Japan and Taiwan) for the life science research and in vitro diagnostics markets enables customers to reliably detect protein biomarkers in extremely low concentrations (5 orders) in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies, and also allows researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations and have been discovered using technologies such as mass spectrometry or other capital instrument . The business opportunity includes co-development, method technology transfer, technology licensing, and IVD applications. We hope to build more strategic partnership with international associates to achieve the mission of FOPPR inside.

We are executing a multinational innovation program, called as “UREKA GlobalStars Taiwan digital industrial collaborations”, in partnership with Centre for Process Innovation (CPI), a British technology and innovation social enterprise, for the purpose of enabling UK industrial digital companies to access, collaborate with and find new markets in Taiwan. Meanwhile, we are in collaboration with global research institutes including Stanford medical center, Brigham and Women's Hospital, Amsterdam UMC, New Castle and University College London in healthcare field. This can help us to provide the information of third-party verification of our technology to pharmaceutical companies so that we can accumulate our capability abundantly for future out-licensing transaction. 

JSC Altechna R&D (brandname - Workshop of Photonics (WOP))

Workshop of Photonics (WOP) — Precision through Femtosecond Laser Innovation

Founded in 2003, Workshop of Photonics (WOP) is a leading provider of femtosecond laser micromachining solutions for both industrial and scientific sectors worldwide. With over 20 years of continuous research and innovation, WOP delivers end-to-end services, from feasibility studies and rapid prototyping to high-precision micromachining services and fully customized femtosecond laser workstations.

WOP specializes in:

  • Ultrashort Pulse Laser Technologies for high-precision industrial manufacturing.

  • Laser micromachining solutions for industries including Semiconductor, Biotech, Automotive, Medical Devices, and Optical Communications.

  • Tailored femtosecond laser workstations for:

    • Glass, sapphire, and silicon wafer micromachining (dicing, drilling, structuring)

    • Fiber Bragg Grating (FBG) inscription

    • Waveguide writing

    • Custom materials and applications.

With a strong foundation of scientific excellence — backed by numerous research articles, patents, and deep theoretical and practical knowledge — WOP is not only following but actively shaping trends in ultrashort pulse laser technology.

Our Global Vision — Stronger Ties with Taiwan

WOP has been actively expanding its presence in Taiwan, building connections with integrators, end-users, and trading companies. We are enthusiastic about participating in the X-Talent Program, as it represents a valuable opportunity to strengthen the ties between Lithuania and Taiwan, and foster deeper collaboration in precision engineering and laser technology.

Kneron, Inc.

Established in 2015, Kneron is a leading provider of full stack edge AI solutions based in San Diego. Kneron was the winner of Tengfei Award by Tencent and won the third place in Innovation Competition of International Talents, Silicon Valley Division.We are dedicated to the development of integrated edge AI hardware and software solutions for vehicle, security, and broader AIoT use cases. Our mission is to empower the proliferation of accessible, low-latency, and secure AI applications by creating networks of independently intelligent devices as enabled through full stack Kneron solutions.

Lightel Technologies Inc.

LIGHTEL — Empowering the Future of Fiber Optics

Since 1999, LIGHTEL has been a trusted global partner in the fiber optics and photonics industries. From our roots in developing Coupler Workstations for Fused Biconic Taper (FBT) production, we have grown into a leading provider of cutting-edge fiber optic components and inspection solutions. Our portfolio includes Fused Fiber and Micro-Optic passive components, advanced Video Microscopes, and a wide range of solutions serving the Optical Communications, Fiber Laser, and Space Laser Communication sectors.

Located in the Greater Seattle area, LIGHTEL is driving the next wave of innovation with a strong focus on high-power (kW-class) fiber laser technologies. Our advanced solutions are tailored to meet the evolving needs of Industry 4.0, Intelligent Manufacturing Systems (IMS), and Autonomous Vehicle applications.

With decades of expertise and a passion for innovation, LIGHTEL is committed to helping industries worldwide achieve faster, smarter, and more reliable optical solutions.

MSS USA CORP

MSS USA CORP, established in May 2024, is a subsidiary of MSSCORPS CO., LTD. We uphold our parent company’s tradition of delivering precise and prompt analytic services with exceptional quality to clients in the semiconductor industry, positioning ourselves as the premier R&D partner in this sector.
Our core service is Transmission Electron Microscopy (TEM) analysis, which provides comprehensive structural (TEM/STEM imaging modes), chemical (EDS), and dimensional (auto CD measurements) information on materials of interest. Leveraging our proprietary and patented sample protection strategy, along with advanced FIB sample preparation techniques, we offer accurate TEM analysis for both hard and fragile materials used in cutting-edge technology developments, such as low-k dielectrics and EUV photoresists. This specialized analytic method furnishes R&D engineers with crucial insights, accelerating their development processes.
We recognize that the protection of proprietary information (PIP) is of utmost importance. MSS USA adheres to the same rigorous PIP control procedures as its parent company, which has earned the trust and recognition of numerous world-renowned semiconductor companies. Every piece of information, including provided materials, samples, data, and analytic history, is meticulously recorded, securely stored, and robustly protected. MSS USA remains a trusted R&D metrology partner for companies that prioritize the safeguarding of their proprietary information.
By expanding into the US market, we bring our expertise closer to our clients, enhancing collaboration and fostering innovation across the semiconductor industry.

Mucker Capital

Mucker Capital started about 10 years ago and has grown from an accelerator to cover everything from pre-seed to series A investments, including Honey (acquired by PayPal for $4B), ServiceTitan (last valued at $9.5B), and Emailage (acquired by LexisNexis parent RELX for $500M). As one of the top early-stage venture Capital firms in the US, Mucker's portfolio companies have raised a total $8 billion in additional outside funding.

ONYX Healthcare USA, Inc.

Onyx Healthcare USA, a key subsidiary of the ASUS Computer Group, is dedicated to advancing healthcare through cutting-edge, medically certified computing solutions. With over 15 years of expertise in embedded technology and medical-grade design, Onyx empowers the healthcare industry with high-performance, fanless computing platforms engineered to meet the most demanding clinical environments.

From the operating room to bedside care, Onyx delivers a comprehensive portfolio of UL/EN60601-1 and ISO13485-certified solutions, including:

  • Surgical Workstations

  • Slim Medical Fanless Panel PCs

  • Medical Tablet PCs

  • Bedside Infotainment Terminals

  • Embedded Motherboards

  • Customized OEM/ODM Solutions

Onyx Healthcare seamlessly integrates design, manufacturing, and innovation to optimize workflows across surgery suites, nursing stations, patient wards, ambulatory care, and hospital management. Our systems are purpose-built to meet global regulatory standards (CE, FCC Class B, CSA), ensuring safety, reliability, and longevity.

Powered by the technological legacy of the ASUS Group and a commitment to innovation, Onyx Healthcare USA is shaping the future of Healthcare IT and Medical OEM — enabling next-generation smart hospitals worldwide.

Polaris Electro-Optics

At Polaris Electro-Optics, Inc., we believe that overcoming society’s greatest challenges requires mastery of the creation, movement, and use of information. We are mastering the movement of information by leveraging patented material and design innovations to offer the highest-speed, most energy efficient integrated photonics products to the communications and computation industries. Our goal is to define the standard for moving information. We work hard in a collaborative, cross-functional team environment, and value mutual trust and respect built on a foundation of integrity, transparency, consistency, and humility. Additional information about Polaris is available at www.PolarisEO.com.

PathCision Medicine, Inc.

At PathCision Medicine, we are redefining precision medicine by uncovering novel therapeutic targets hidden in tissue pathology. As a Boston-based biopharma startup, we are tackling some of the most pressing challenges in oncology and beyond, developing first-in-class therapies for metastatic cancer and other diseases with high unmet needs.

Our proprietary AI-powered spatial biology platform deciphers complex interactions between diseases and the tissue microenvironment. By integrating tissue pathology with advanced patient multi-omics, we generate insights that lead to clinically actionable and translatable drug candidates.

Our lead asset, a first-in-mechanism antibody-drug conjugate (ADC), selectively targets tumors while sparing healthy tissues — improving both efficacy and safety.

We are now building Version 2 of our discovery engine — a next-generation machine learning platform that will push the boundaries of AI in drug discovery. We're looking for passionate and innovative machine learning engineers to join us in this mission.

If you are excited about applying AI to solve real-world biological problems, impacting patient lives, and growing with a fast-moving biotech startup — PathCision is the place for you.

PharmaEssentia Innovation Research Center

PharmaEssentia Corporation is a rapidly growing biopharmaceutical company dedicated to transforming the treatment landscape for patients with challenging diseases in hematology and oncology. By combining deep scientific expertise with proven biological principles, we are delivering innovative therapies — including one approved product and a robust, diversifying pipeline. We are committed to improving both health outcomes and quality of life for patients worldwide.

Founded in 2003 by a team of Taiwanese-American executives and leading scientists from top U.S. biotechnology and pharmaceutical companies, PharmaEssentia has since grown into a global biopharma innovator. We are publicly listed on the Taipei Exchange (TPEx: 6446) and operate across key regions including the United States, Japan, China, and Korea. Our biologics are manufactured in a state-of-the-art GMP-certified production facility in Taichung, Taiwan.

In 2022, PharmaEssentia established the PharmaEssentia Innovation Research Center (PIRC) in the Greater Boston Area — one of the world's most vibrant biotech hubs. Fully funded by PharmaEssentia, PIRC is home to a world-class drug discovery team led by industry veterans recruited from leading pharmaceutical companies such as Sanofi, Pfizer, Merck, AbbVie, and Eisai. As PIRC continues to grow, it serves as a vital engine for accelerating our innovation in biologics and expanding our global footprint.

Taboola

Taboola is an AI-powered discovery platform serving over 600 million daily active users and delivering more than 450 billion personalized recommendations every month across the open web. Our mission is to help people discover content, products, and experiences they’ll love — when they are most likely to engage.

At the core of Taboola's platform is a sophisticated machine learning recommendation engine that processes massive-scale data in real time. Every second, our AI analyzes hundreds of signals — including user behavior, content semantics, contextual information, and collaborative trends — to optimize the match between users and content. This system continuously learns and adapts, ensuring relevant and high-quality recommendations across websites, devices, and mobile applications.

Our platform powers discovery for the world’s top publishers and digital properties, such as Yahoo, CNBC, BBC, NBC News, Business Insider, and The Independent. Taboola also drives e-commerce recommendations, enabling over 1 million monthly transactions for major brands like Walmart, Macy’s, Skechers, and eBay.

Founded in 2006 and listed on NASDAQ (TBLA), Taboola is headquartered in New York City with a global footprint, including R&D in Tel Aviv, Los Angeles, Hungary, and Taipei. Our team of engineers, data scientists, and AI researchers tackle some of the most exciting challenges in real-time large-scale recommendation systems, AI-driven personalization, and online monetization.

Join us as we push the boundaries of AI at scale and shape the future of discovery on the open web.

Tachyum s.r.o.

At Tachyum, we are building what others said was impossible — the world's first Universal Processor, Prodigy™, designed to power AI, HPC, and Cloud workloads beyond anything on the market.

Prodigy unifies CPU, GPU, and AI accelerator capabilities into a single chip, delivering:

  • 3x performance boost over existing processors.

  • Up to 10x lower power consumption, solving one of the biggest pain points in modern data centers.

  • A fully homogeneous architecture, eliminating the need for separate GPUs or TPUs.

  • The ability to dynamically switch between cloud services and AI workloads — running data centers 24/7 at peak utilization.

This is not just about performance — it's about redefining the future of computing. Prodigy is designed to scale AI supercomputers to a level faster than the human brain, enabling a new era for deep learning, scientific computing, and hyperscale infrastructure.

Your Impact

By joining Tachyum, you will work directly on:

  • AI workloads at scale — powering the world's largest AI supercomputers.

  • Advanced compiler and system-level optimizations to unify traditional and AI workloads.

  • Next-gen chip architecture, breaking the boundaries between CPU, GPU, and AI accelerators.

  • Energy-efficient computing, solving global challenges in power consumption and sustainability.

Why Tachyum?

  • Founders & technical leaders with deep roots at Nvidia, AMD, Intel, Skyera, and SandForce.

  • Hands-on opportunity to build a global-scale AI platform from silicon to system.

  • Collaborate with engineering teams across Silicon Valley, Slovakia, Czech Republic, and Las Vegas.

  • Direct impact on the future of AI and HPC infrastructure, solving real-world challenges in compute, power, and scalability.

Tachyum is not just another chip company — we are shaping the next generation of AI and cloud infrastructure. If you are passionate about large-scale systems, AI performance, hardware-software co-design, and solving problems that truly matter — we want you on our team.

Vizuro LLC

Vizuro is an innovator and solution provider of Multimodal, Causal GenAI with its powerful applications in diverse sectors. We utilize our proprietary self-learning, explainable and actionable AI on a managed, data-science-as-a-service platform to quickly deploy bespoke applications in an expedited timeframe. We serve global clients in various sectors and sizes, ranging from Fortune 100 enterprises to startups
 

more
back to top